PPIDT00158
Drug Information
| Name | Ramucirumab |
|---|---|
| Sequence | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB05578 |
| Type | biotech |
| Indication | Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with [paclitaxel] for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with [erlotinib], for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor exon 19 deletions or exon 21 (L858R) point mutations. It is also indicated in combination with [docetaxel] for the treatment of metastatic non-small cell lung cancer in patients who have progressed following prior platinum-based chemotherapy. Patients who have EGFR or ALK genomic aberrations should also have disease progression following FDA-approved therapy for these aberrations. Ramucirumab, in combination with FOLFIRI ([folinic acid], [fluorouracil], and [irinotecan]), is indicated for the treatment of metastatic colorectal cancer in patients who have progressed following therapy with [bevacizumab], [oxaliplatin], and a fluoropyrimidine. Lastly, ramucirumab is indicated for the treatment of hepatocellular carcinoma in patients with an alpha-fetoprotein level ≥400 ng/mL and have previously been treated with [sorafenib].[L40938] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
10 mg/mL
|
| Injection, solution, concentrate | Intravenous; Parenteral |
10 MG/ML
|
| Solution | Intravenous |
10 mg / mL
|
| Solution | Intravenous |
10 mg/1mL
|
| Solution | Intravenous |
10.000 mg
|
| Injection | Parenteral |
100 mg/10ml
|
| Injection, solution, concentrate | Intravenous |
100 mg/10ml
|
| Injection | Parenteral |
500 mg/50ml
|
| Injection, solution, concentrate | Intravenous |
500 mg/50ml
|
| Injection, solution, concentrate | Intravenous |
10 mg/ml
|
| Solution, concentrate | Intravenous |
1000000 mg
|
| Injection, solution, concentrate | Intravenous |
10 mg/1ml
|